The Ethics of Anti-aging Clinical Trials

Original Paper

Abstract

Interventions aiming to slow, stop, or reverse the aging process are starting to enter clinical trials. Though this line of research is nascent, it has the potential to not only prevent prolonged human suffering, but also to extend human well-being. As this line of research develops, it is important to understand the ethical constraints of conducting such research. This paper discusses some of these constraints. In particular, it discusses the ethical difficulties of conducting this research in a way that would produce reliable data regarding the effectiveness of an anti-aging intervention. Clinical trials of such interventions, I argue, will be faced with a dilemma between two confounding variables. Eliminating the variables requires introducing ethically problematic research practices. Thus, researchers must either perform research in ethically problematic ways, or forego the conduct of high-impact clinical research on anti-aging interventions.

Keywords

Informed consent Study design Research ethics Health behavior 

References

  1. Anisimov, V. N., Berstein, L. M., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Zabezhinski, M. A., et al. (2008). Metformin slows down aging and extends life span of female SHR mice. Cell Cycle, 7(17), 2769–2773.CrossRefGoogle Scholar
  2. Carpenter, C. J., 2010. A meta-analysis of the effectiveness of health belief model variables in predicting behavior. Health Communication, 25(8), pp.661–669. http://dx.doi.org/10.1080/10410236.2010.521906.
  3. Janz, N. K. & Becker, M. H., 1984. The health belief model: A decade later. Health Education and Behavior, 11(1), pp.1–47. http://heb.sagepub.com/content/11/1/1.abstract.
  4. Martin-Montalvo, A., et al. (2013). Metformin improves healthspan and lifespan in mice. Nature communications, 4, 2192.CrossRefGoogle Scholar
  5. Metformin in longevity study—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02432287 [Accessed September 1 2016].
  6. Mills, K. F., Yoshida, S., Stein, L. R., Grozio, A., Kubota, S., Sasaki, Y., et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6), 795–806. doi:10.1016/j.cmet.2016.09.013.CrossRefGoogle Scholar
  7. Rosenstock, I. M., Strecher, V. J., & Becker, M. H. (1988). Social learning theory and the health belief model. Health Education and Behavior, 15(2), 175–183.CrossRefGoogle Scholar
  8. The Belmont report. http://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/ [Accessed September 1 2016].
  9. WMA declaration of Helsinki, ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ [Accessed September 1 2016].
  10. Yoshino, J. et al. (2016). Nicotinamide mononucleotide, a Key NAD+ Intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4), pp.528–536. http://dx.doi.org/10.1016/j.cmet.2011.08.014.

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Missouri School of Dentistry and Oral HealthA.T. Still UniversityKirksvilleUSA

Personalised recommendations